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Abstract
Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes
in normal discoid shape of erythrocytes and hemolytic anemia. This work evaluates the effects of TAM on isolated human
erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of
biomembranes in its cytostatic action mechanisms. TAM induces hemolysis of erythrocytes as a function of concentration.
The extension of hemolysis is variable with erythrocyte samples, but 12.5 WM TAM induces total hemolysis of all tested
suspensions. Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes.
The hemolytic effect of TAM is prevented by low concentrations of K-tocopherol (K-T) and K-tocopherol acetate (K-TAc)
(inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage. This
was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-
induced hemolysis. Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by
AAPH, thus ruling out TAM-induced cell oxidative stress. Hemolysis caused by TAM was not preceded by the leakage of
K from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility
curves. However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially
bound to band 3. Either K-T or K-TAc increases membrane packing and prevents TAM partition into model membranes.
These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in
condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided. Therefore, TAM-
induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the
erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane. These defects explain the abnormal
erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia. Additionally, since
membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM
may contribute to the multiple mechanisms of its anticancer action. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Tamoxifen (TAM) is a synthetic non-steroidal
antiestrogen widely used in the chemotherapy of
breast cancer [1]. The established e⁄ciency and low
incidence of side e¡ects allowed the use of TAM as a
chemopreventive drug [2]. Recently, it was reported
that TAM induces multiple cellular adverse e¡ects,
including changes in normal discoid shape of eryth-
rocytes with formation of stomatocytes, meaning
that the drug may insert in the inner lea£et of the
erythrocyte membrane [3]. Additionally, it has been
suggested that TAM causes hemolytic anemia
[4,5], but the biochemical mechanisms were not iden-
ti¢ed.
The antiproliferative e¡ects of TAM and other
triphenylethylene derivatives in estrogen-dependent
breast cancer cells are believed to be mediated by
high a⁄nity binding to the estrogen receptor (ER),
thereby blocking the growth stimulating action of
estradiol [6]. However, TAM also inhibits the growth
of ER-negative breast cancer cells and other cell
types which lack ER [7^10]. Furthermore, in some
ER-positive and ER-negative cell lines, the antipro-
liferative e¡ect of TAM is not overcome by estrogen
addition [8,11]. Moreover, the mechanisms underly-
ing the ER-independent inhibition of tumor cell
growth by TAM also remain obscure. Thus, exten-
sive studies have been performed and multiple cellu-
lar e¡ects have been described, namely, binding to
antiestrogen binding sites [12,13], inhibition of pro-
tein kinase C [14,15], inhibition of a nucleoside trans-
porter protein [16], inhibition of cAMP phosphodies-
terase [17,18], antagonism of calmodulin by a direct
interaction with this protein [19] and induction of
apoptosis [20,21].
Biomembranes, where TAM strongly incorporates
[22] interacting with lipids [23] and proteins [19,24],
have been suggested as a potential target for TAM
action [25]. Indeed, TAM induces early modi¢ca-
tions in the morphology and structure of breast tu-
mor cell membranes putatively related with its anti-
proliferative activity [26]. Moreover, TAM has been
reported to disrupt unspeci¢cally the structure of
model membranes [24,27] and the permeabilization
of the mitochondria and the parallel loss of mem-
brane potential induced by TAM has been assigned
to a structural disruption of the mitochondrial mem-
brane [28].
At present, e¡ects of TAM on erythrocyte mem-
brane integrity have not been reported. On the other
hand, it has been ascertained that free radical-medi-
ated peroxidation of erythrocyte membrane lipids
and proteins and changes in cytoskeleton proteins
eventually promote hemolysis. Therefore, the reports
of hemolytic anemia caused by TAM alone [4] or in
combination with mitomycin C, not related to bone
marrow toxicity [5], prompted us to search the e¡ects
of TAM on isolated human erythrocytes, particularly
on the potential oxidative disruption and physical
damage of cell membrane and the protection af-
forded by antioxidants or membrane stabilizers, e.g.
K-tocopherol (K-T) and K-tocopherol acetate (K-
TAc). Thus, the aim of these studies was to contrib-
ute for the elucidation of the underlying mechanisms
of TAM-induced hemolytic anemia and to clarify the
role of biomembranes in its cytostatic action mecha-
nisms.
2. Materials and methods
2.1. Chemicals
Tamoxifen, 1,6-diphenyl-1,3,5-hexatriene (DPH),
HEPES, acrylamide, Coomassie brilliant blue R-
250, K-tocopherol acetate (K-TAc) and protein
markers for molecular weight were obtained from
Sigma (St. Louis, MO, USA). 9,11,13,15-Octadeca-
tetraenoic acid (cis-parinaric acid) (PnA) and 3-
[p-(6-phenyl)-1,3,5-hexatrienil]-phenylpropionic acid
(DPH-PA) were from Molecular Probes (Junction
City, OR). 2,2P-Azobis(2-amidinopropane)dihydro-
chloride (AAPH) was obtained from Polysciences
(Warrington, PA). K-Tocopherol (K-T) was pur-
chased from Fluka, Switzerland. Bisacrylamide,
TEMED, ammonium persulfate and glycine were
from Merck (Darmstadt). All the other chemicals
were of research grade. Solutions were prepared in
deionized ultra pure water.
2.2. Preparation of erythrocyte suspensions
Freshly collected human blood, obtained from
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12 healthy donors (25^50 years old and not submit-
ted to any drug treatment) who are working in our
laboratory, was mixed with heparin and centrifuged
at 3000 rpm/10 min to separate plasma and erythro-
cytes. The retrieved erythrocytes were washed three
times with 6 vols. of the isotonic phosphate bu¡ered
saline (PBS) (150 mM NaCl, 10 mM sodium phos-
phate, pH 7.4). The bu¡y coat was carefully removed
with each wash. After the last washing, the packed
cells were re-suspended in PBS and the hematocrit
determined. The erythrocyte suspensions used in ex-
periments were prepared daily.
2.3. Osmotic fragility and hemolysis measurements
The osmotic fragility assays were performed in
phosphate bu¡er solutions (10 mM sodium phos-
phate, pH 7.4) containing increasing concentrations
of NaCl and hematocrit of 0.33%. The hemolysis
experiments were carried out in erythrocyte suspen-
sions (4 ml) in PBS with hematocrit of 0.33%. The
protective e¡ects of K-T and K-TAc were assessed by
preincubating the erythrocyte suspensions with these
tocopherols at 37‡C/2 h before TAM addition. In a
set of samples, the erythrocytes preincubated with
K-T and K-TAc were washed three times with 10 ml
of PBS before the addition of TAM.
TAM was added from a stock ethanolic solution
(2^4 Wl) and incubated with erythrocyte suspensions
at 37‡C for 1 h in a shaking water bath with gentle
magnetic stirring. After incubation, the erythrocyte
suspensions were centrifuged at 3000 rpm/10 min
and hemolysis was estimated from the 540 nm absor-
bance of hemoglobin released into the supernatant.
The results were expressed as % hemolysis. Zero he-
molysis was taken as the absorbance of the super-
natant of erythrocyte suspensions in isotonic phos-
phate bu¡er in the absence of TAM and 100%
hemolysis was assigned when bu¡er was replaced
by water, containing an identical volume of ethanol
to that used in the experiments with TAM.
The e¥ux of K from the erythrocyte suspensions
was measured with a K ion-selective electrode made
in our laboratory, as described elsewhere [29]. The
total amount of K was determined by the addi-
tion of 0.5% Triton X-100 to the erythrocyte suspen-
sions.
The recordings are typical assays or represent the
mean þ S.D. of three independent experiments.
2.4. Evaluation of oxidative stress in erythrocytes
The putative peroxidation occurring during hemol-
ysis induced by 12.5 WM TAM and the peroxidative
degradation of the lysate induced by 20 mM AAPH
were followed by O2 consumption and by changes in
the hemoglobin absorption spectrum.
The rate of O2 consumption was monitored using
a Clark-type oxygen electrode (YSI model 5331, Yel-
low Spring Institute) as previously described [30].
The reactions were carried out in a closed glass vessel
thermostated at 37‡C, provided with magnetic stir-
ring and the hemolysis of erythrocyte suspension
(0.33% hematocrit) was induced by addition of
12.5 WM TAM. After 60 min of TAM addition, the
azoinitiator AAPH (20 mM) was added and O2 con-
sumption was followed for another period of 60 min.
Oxygen consumption was calculated assuming an O2
concentration of 177 nmol/ml at 37‡C.
During the incubation of erythrocyte suspensions
with 12.5 WM TAM and also after addition of 20 mM
AAPH, aliquots of the suspension were taken up,
centrifuged at 3000 rpm/5 min and the hemoglobin
spectrum was analyzed in the supernatant. With-
drawn aliquots were chilled before centrifugation to
stop the thermal decomposition reaction of the azo-
initiator. Hemoglobin oxidation was followed by the
decay of the absorption spectrum at 450^650 nm
using a Perkin-Elmer Lambda 6 UV/VIS spectropho-
tometer (Norwalk, USA).
The oxidation of 1.5 WM PnA incorporated in the
membrane of intact erythrocytes (0.05% hematocrit)
was induced by 1 mM AAPH at 37‡C. TAM (10 WM)
was preincubated with the erythrocyte suspension at
37‡C/2 min before addition of PnA. After 90 s of
recording the basal signal, PnA was added and £uo-
rescence intensity was monitored using a Perkin-
Elmer LS-50 spectro£uorimeter provided with ther-
mostated cuvettes and magnetic stirring. The excita-
tion was set at 312 nm and the emission at 450 nm.
The excitation and emission slit widths were 5 and
15 nm, respectively. Experiments of spontaneous
£uorescence decay of PnA (blank) and in the absence
of drug (control) were performed. The experimental
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conditions used were previously established to ascer-
tain that the £uorescence intensity of incorporated
PnA is linear with its concentration and that the
hematocrit is high enough to incorporate most of
the probe. The excitation and emission conditions
used minimize the £uorescence quenching promoted
by hemoglobin.
2.5. Partition coe⁄cient and £uorescence polarization
The partition coe⁄cient (Kp) of TAM was deter-
mined by means of second derivative UV spectro-
photometry, enabling the quanti¢cation of the drug
in the lipid phase as previously described [22].
DMPC liposomes and liposomes containing K-T or
K-TAc were prepared, after solvent evaporation to
dryness, by dispersion in 50 mM NaCl, 10 mM
HEPES, pH 7.4. The lipid suspensions were obtained
as described elsewhere [22], except that liposomes
were vortexed and sonicated during four bursts of
2 min and left to equilibrate overnight at 4‡C before
use.
The £uorescent probes of membrane £uidity DPH
and DPH-PA were incorporated at 37‡C/3 h into
DMPC liposomes (345 WM in phospholipid) as de-
scribed elsewhere [23]. Liposomes without or con-
taining K-T and K-TAc were prepared as described
above by dispersion in 50 mM KCl and 10 mM Tris-
maleate, pH 7 [31]. The lipid/probe molar ratio was
about 400. The £uorimetric measurements were car-
ried out in a Perkin-Elmer LS-50 spectro£uorimeter
(Beacons¢eld, UK) and the excitation was set at 336
nm and the emission at 450 nm, being the band
widths 3 and 4 nm, respectively. The degree of £uo-
rescence polarization (P) was determined as reported
elsewhere [32]. Adequate control experiments were
carried out without added probes to correct for the
contribution of light scattering.
TAM was incubated with liposomes at 37‡C for
20 min before Kp and P measurements. The values
are the mean of three independent experiments.
2.6. SDS-polyacrylamide gel electrophoresis
SDS-polyacrylamide slab gels were prepared ac-
cording to the procedure of Laemmli [33]. The slab
gel consisted of a 5% polyacrylamide stacking gel
and a 10% polyacrylamide separating gel.
Ghost membranes were prepared from erythrocyte
suspensions lysed at 37‡C/1 h in absence (control)
and presence of 12.5 WM TAM and centrifuged at
15 000 rpm/20 min. Hemolysis in control assay was
carried out in hypotonic bu¡er. In either case, the
erythrocyte membranes were washed twice with
20 ml of hypotonic phosphate bu¡er and centrifuged
at 19 000 rpm/20 min. The protein of ghosts re-sus-
pended in PBS was estimated by the biuret method
[34] in the presence of SDS, using bovine serum al-
bumin as standard and adjusted at 1.5 mg/ml. Slab
gels were stained with Coomassie brilliant blue R-250
and destained with a mixture of 25% methanol and
5% acetic acid.
3. Results and discussion
3.1. TAM e¡ects on osmotic fragility and hemolysis
of human erythrocytes
The interactions of TAM with biomembranes have
been reported to contribute to its multiple cellular
e¡ects [23,24,27]. Recently, we suggested that mito-
chondrial swelling and membrane potential depolari-
zation induced by TAM re£ect a direct action of this
drug on the inner membrane structure [28]. There-
Fig. 1. E¡ect of TAM on the osmotic fragility of human eryth-
rocytes. Erythrocyte suspensions (0.33% hematocrit) in 10 mM
phosphate bu¡er containing increasing concentrations of NaCl
were incubated at 37‡C/1 h in the absence (control) (a) and in
the presence of 7.5 WM TAM (b). Hemolysis was calculated
from the 540 nm absorbance of the supernatant after centrifu-
gation of the erythrocyte suspensions and the results expressed
as percentage of total hemolysis.
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fore, to con¢rm the potential relationship between
hemolytic anemia and membrane structural defects
induced by TAM, the e¡ects of this drug on the
osmotic fragility and hemolysis of human erythro-
cytes were studied.
The e¡ects of TAM on the osmotic fragility, eval-
uated from the curves of hemolysis as a function of
NaCl concentration, are shown in Fig. 1. Incubation
of 7.5 WM TAM with the erythrocyte suspensions
induces a maximum of 20% hemolysis in the isotonic
range. However, TAM does not shift the osmotic
fragility curve as compared to erythrocytes incubated
in the absence of drug (control), indicating that
TAM does not modify the susceptibility of erythro-
cytes to hypotonic osmotic lysis. Therefore, the he-
molytic e¡ect of TAM observed in the isotonic range
is not assigned to changes in osmotic membrane per-
meability, in agreement to K e¥ux data monitored
in parallel to hemoglobin release (Fig. 2). As shown
in this ¢gure, the K leakage curve resulting from
the incubation of erythrocyte suspensions with 10
WM TAM at 37‡C is very close to the hemolysis
curve. The similar rates of K and hemoglobin re-
lease strongly exclude the lateralization or redistrib-
ution of transmembrane proteins into clusters or ag-
gregates induced by TAM, leading to the formation
of pores and consequent colloid-osmotic lysis, a
mechanism that has been well characterized over
the last decade for potent membranolytic agents
[35]. Rather, the results support the concept of
TAM-induced hemolysis occurring via direct mem-
brane disruption.
The hemolysis induced by TAM on erythrocytes
suspended in isotonic medium (PBS) was studied as
a function of incubation time and drug concentration
in several erythrocyte suspensions obtained from dif-
ferent donors (Fig. 3, lines 1^4). As shown in Fig.
3A, incubation of red cells with 10 WM TAM at 37‡C
results in a time-dependent hemolysis and, although
the extension of hemolytic e¡ect depends on blood
Fig. 2. Time courses of K (- - - ) and hemoglobin (9) release
from erythrocytes in 150 mM NaCl, 10 mM sodium phosphate,
pH 7.4 (0.33% hematocrit), incubated with 10 WM TAM at
37‡C. Release of K and hemoglobin were measured with a
K ion-selective electrode and by spectrophotometry of the
supernatant at 540 nm, respectively. The results are expressed
as percentage of total release observed in total hemolysis.
Fig. 3. Hemolytic e¡ect of TAM on human erythrocytes ob-
tained from di¡erent donors (lines 1^4) in 150 mM NaCl,
10 mM sodium phosphate, pH 7.4 (0.33% hematocrit). Erythro-
cyte suspensions were incubated with 10 WM TAM at 37‡C as
a function of time (A) and at 37‡C/1 h as a function of drug
concentration (B). Hemolysis was calculated from the 540 nm
absorbance of the supernatant after centrifugation of the eryth-
rocyte suspensions and the results expressed as percentage of
total hemolysis.
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donor, it reaches a maximum after 1 h of incubation
with the drug for all the samples. The hemolysis ex-
tension induced by TAM is slower for old subjects
(more than 40 years old) (Fig. 3A, lines 3^4), accord-
ing to other studies pointing that the sensitivity to
hemolysis decreases as a function of age while the
membrane cholesterol content, that strongly de-
creases TAM partitioning in biomembranes [22], in-
creases with age. The hemolysis is drug concentra-
tion-dependent and complete hemolysis occurs at
12.5 WM TAM incubated at 37‡C for 1 h (Fig. 3B),
independently of the erythrocyte donor.
It has been reported that TAM partitions strongly
in biomembranes [22] and that in humans the levels
of TAM are 10^60-fold higher in tissues than in se-
rum (1 WM) [36]. Thus, at high concentrations in
vivo, probably the excessive incorporation of TAM
may disrupt the erythrocyte membrane and cause
extensive hemolysis. Indeed, TAM-induced hemolytic
anemia observed in patients under TAM therapy
might be consequence of a direct e¡ect on erythro-
cyte membrane, resulting in the disruption of mem-
brane structure.
To ascertain the potential mechanisms of TAM-
induced erythrocyte hemolysis, as putative oxidative
disruption and physical perturbation, the e¡ects of
antioxidants and membrane stabilizers, e.g. K-T
and K-TAc, were studied. The hemolytic e¡ect of
TAM is inhibited by low concentrations of K-T pre-
viously incorporated into erythrocytes (Fig. 4A).
When erythrocytes were washed after preincubation
with K-T, the protection against TAM-induced he-
molysis is maintained and K-T exhibits nearly the
same inhibitory e¡ects as in unwashed erythrocytes.
K-T is more e¡ective in suppressing hemolysis than
K-TAc since 2 WM K-T inhibits about 80% hemolysis
(Fig. 4A) and the same e¡ect is observed only at 15
WM K-TAc (Fig. 4B). After washing of erythrocytes
to rule out any interference by free K-TAc, small
di¡erences are observed on K-TAc protective e¡ects
as compared to unwashed erythrocytes, except for
concentrations below 5 WM K-TAc. These observa-
tions indicate that K-T, with a selective uptake sys-
tem in red blood cells [37], and K-TAc incorporate
deeply into the erythrocyte membrane and are not
signi¢cantly released by washing. Therefore, the pro-
tective e¡ects of tocopherols against TAM-induced
hemolysis probably result from interaction of toco-
pherols in the membrane core, excluding any surface
action. Hence, the hydroxyl group of K-T is not crit-
ical for protection of membrane against TAM-in-
duced damage, but rather the chroman ring, accord-
ing to the e¡ects described elsewhere for inhibition of
retinol-induced hemolysis [38].
K-T is a widespread naturally occurring compound
that acts as the major lipophilic antioxidant in bio-
logical systems because of its ability to interrupt the
peroxidative process [39]. Moreover, this compound
has been shown to inhibit lipid peroxidation in hu-
man erythrocyte membranes [40] and to prevent he-
molysis induced by oxygen free radicals [41]. Since K-
T e⁄ciently inhibits the hemolytic e¡ect of TAM, the
Fig. 4. Inhibition of TAM-induced hemolysis by K-tocopherol
(A) and K-tocopherol acetate (B). Erythrocyte suspensions in
150 mM NaCl, 10 mM sodium phosphate, pH 7.4 (0.33%
hematocrit) were preincubated with tocopherol compounds at
37‡C/2 h and the erythrocytes were washed (b) or not (a) be-
fore the addition of 10 WM TAM as indicated in Section 2. The
hemolysis extension induced by TAM incubated at 37‡C/1 h
was measured as described in the legend of Fig. 1. Data repre-
sent the mean þ S.D. of three di¡erent erythrocyte preparations.
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oxidative damage of erythrocytes could in principle
be involved in TAM-induced hemolysis. However,
TAM is a potent intramembranous inhibitor of lipid
peroxidation in model membranes, acting as a per-
oxyl radical scavenger [30], and an e⁄cient inhibitor
of DNA oxidation [42]. Additionally, K-TAc, with
the hydroxyl group blocked and hindered of antioxi-
dant activity, also inhibits this hemolytic e¡ect, prob-
ably as a consequence of membrane structure stabi-
lization. A major e¡ect of tocopherols is, however,
related with withdrawal of TAM from incorporating
in the membrane since the partition coe⁄cient is
strongly decreased by the tocopherol incorporation
occurring at similar putative domains across the
membrane structure. Therefore, these observations
might suggest that TAM-induced hemolysis is not
assigned to an oxidative disruption of the erythrocyte
membrane.
3.2. TAM e¡ects on peroxidative degradation of
erythrocytes
To further clarify the possible involvement of free
radicals in the hemolytic e¡ect of TAM, oxygen con-
sumption and hemoglobin oxidation were monitored
in parallel during the time course of hemolysis in-
duced by the drug. As observed in Fig. 5A, the he-
molysis induced by 12.5 WM TAM is not accompa-
nied by O2 consumption or changes in the spectra of
the hemoglobin released to the supernatant (Fig. 5B).
In contrast, when the generator of peroxyl radicals
AAPH is added to the incubation medium, an abrupt
O2 consumption is initiated (Fig. 5A) and a gradual
conversion of the typical spectra of oxyhemoglobin
into that of Met-hemoglobin is observed (Fig. 5C),
suggesting an extensive peroxidation of lipids and
proteins induced by the radicals generated by
AAPH. Clearly, TAM is totally silent regarding oxi-
Fig. 5. Rate of oxygen consumption associated with hemolysis
of erythrocytes induced by 12.5 WM TAM and by 20 mM
AAPH (A) and spectra of hemoglobin after addition of TAM
(B) and AAPH (C). Erythrocyte suspensions in 150 mM NaCl,
10 mM sodium phosphate, pH 7.4 (0.33% hematocrit) were in-
cubated with TAM and AAPH at 37‡C. O2 consumption (A)
and hemoglobin spectra were monitored simultaneously during
incubation of TAM for 1 h (B) and after AAPH addition (C),
as described in Section 2. Hemoglobin spectra were recorded at
di¡erent reaction times indicated by the numbers adjacent to
the traces. Upward and downward arrows indicate an increase
or decrease in absorbance due to hemoglobin release (B) and
hemoglobin oxidation by AAPH added 1 h after TAM (C).
Fig. 6. E¡ect of 10 WM TAM on the peroxidative degradation
of 1.5 WM PnA incorporated into the membrane of intact er-
ythrocytes (0.05% hematocrit). The peroxidative degradation of
PnA, indicated by its £uorescence decay, was induced by 1 mM
AAPH in the absence (control) and presence of 10 WM TAM
(TAM) and kinetically monitored at 450 nm emission setting
the excitation at 312 nm with 15 and 5 nm slits, respectively.
The dashed line shows the spontaneous £uorescence decay of
PnA at 37‡C (Blank). The recordings are typical assays of three
independent experiments.
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dative challenge of erythrocytes as compared to
AAPH.
To emphasize this observation, the e¡ect of TAM
on the peroxidative process induced by AAPH in
intact erythrocytes was studied by the £uorescence
intensity decay of PnA. As can be observed (Fig.
6), the addition of AAPH to erythrocyte suspension
in the absence of TAM (control) induces a decrease
in PnA £uorescence relative to the spontaneous £uo-
rescence decay of PnA (blank), which is related to
the rate of its oxidative degradation [30]. Preincuba-
tion of TAM with erythrocytes decreases the rate of
£uorescence intensity decay of PnA as compared to
the control, indicating an e⁄cient antioxidant activ-
ity of TAM in the ¢rst stages of erythrocyte mem-
brane lipid peroxidation. Identical antioxidant e¡ect
of TAM is also noticed in the hemolysate peroxida-
tion induced by AAPH as evaluated by O2 consump-
tion (Fig. 7). Exposing the hemolysate to AAPH-de-
rived radicals results in lipid peroxyl radical
production due to peroxidation as indicated by an
increased rate of O2 consumption as compared to
experiments in the absence of erythrocytes (Fig. 7).
The preincubation of TAM with the hemolysate
leads to a signi¢cant concentration-dependent de-
crease in the rate of O2 uptake pointing to a strong
scavenger capacity of TAM for lipid peroxyl radicals
generated by AAPH as previously described [30].
However, the oxidation of oxyhemoglobin to Met-
hemoglobin in the hemolysate induced by AAPH
(Fig. 8A) is not protected by the presence of TAM
(Fig. 8B) as detected by the hemoglobin spectra re-
corded in parallel to O2 consumption. This inability
of TAM to scavenge peroxyl radicals in aqueous
phase, occurring identical hemoglobin oxidation in-
duced by AAPH in the absence (Fig. 8A) and pres-
ence of TAM (Fig. 8B), strongly corroborates the
intramembranous scavenger properties of TAM in
model membranes previously described [30].
Fig. 7. E¡ect of TAM on the oxidation of hemolysate induced
by 20 mM AAPH at 37‡C, as evaluated by O2 consumption.
The hemolysate was prepared from a 0.33% erythrocyte suspen-
sion by hypotonic hemolysis. O2 consumption was monitored
by a Clark-type oxygen electrode either in the absence (0 WM)
or presence of 12.5 and 20 WM TAM, preincubated at 37‡C/20
min before AAPH addition. Results shown are representative
of three experiments.
Fig. 8. E¡ect of TAM on spectral changes of hemoglobin upon
reaction of hemolysate with 20 mM AAPH at 37‡C. The hemo-
lysate was prepared from a 0.33% erythrocyte suspension by
hypotonic hemolysis and AAPH was added in the absence (A)
and presence of 20 WM TAM preincubated at 37‡C/20 min be-
fore oxidant addition (B). Hemoglobin absorption spectra were
recorded at di¡erent incubation times, indicated by the numbers
close to the traces. Downward and upward arrows indicate a
decrease or increase in absorbance as the reaction proceeds. Re-
cordings are typical of several experiments.
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Therefore, these results indicate that TAM in-
duced-hemolysis is not associated to an increase in
erythrocyte membrane lipoperoxidation or hemoglo-
bin oxidative degradation induced by the drug. How-
ever, they do not exclude the possibility that TAM-
induced hemolysis may result from modi¢cations on
erythrocyte membrane proteins and changes on the
framework of cytoskeleton and/or plasma membrane
proteins.
Previous studies have suggested that membrane
proteins are primary targets in cytolysis [43]. Thus,
the possibility that TAM-induced hemolysis may
occur from interaction with erythrocyte membrane
proteins was examined by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE). This methodology,
allowing polypeptide separation as a function of its
molecular weight, has been used to study alterations
of erythrocyte membrane proteins [44,45], e.g. pro-
tein fragmentation and/or polymerization indicated
by new bands of lower or higher molecular weight,
respectively [40,45].
Fig. 9 shows the electrophoretic pro¢le of the er-
ythrocyte membrane proteins isolated from erythro-
cyte suspensions hemolysed in hypotonic bu¡er (con-
trol) and after hemolysis with 12.5 WM TAM
incubated at 37‡C/1 h (TAM). It is clear that TAM
did not promote the appearance of new bands of
higher or lower molecular weight as compared to
the banding pattern of control, suggesting that
TAM does not induce polymerization or fragmenta-
tion of membrane proteins. Additionally, the relative
amounts of spectrin (K and L), bands 3, 4.1, 4.2 and
5 are similar in the absence (control) and presence of
12.5 WM TAM (TAM), indicating minimal changes
of these proteins due to hemolysis induced by TAM.
However, erythrocytes incubated with the drug dis-
play considerable changes in the intensity of some
proteins bound to band 3 in the erythrocyte mem-
brane.
The band 3 protein constitutes the anion channel
that enables bicarbonate to be changed for chloride
and is a binding structure for proteins of the cyto-
skeleton and cytosol. Recent studies showed that
band 4.1 [46], ankyrin, glycolytic enzymes, aldol-
ase and glyceraldehyde-3-phosphate dehydrogenase
(band 6), and hemoglobin [47] bind predominantly,
if not exclusively, to the band 3 tetramer. TAM de-
creases the intensity of bands 6, 7 and 16 kDa (he-
moglobin monomer), inducing changes on cytoskele-
ton^membrane connections and lipid bilayer. The
release or solubilization of some membrane proteins
suggest that TAM changes lipid^protein interactions
in the bilayer and the framework of erythrocyte cy-
toskeleton proteins and plasma membrane. Accord-
ing to the e¡ects in other membrane systems [24],
where TAM strongly partitions [22] and induces
changes in the bilayer geometry [23], binding unspe-
ci¢cally and interacting with several and distinct
membrane proteins [14,19,48], the hemolytic action
of TAM putatively results from perturbation of er-
ythrocyte membrane integrity and structure, by im-
pairing lipid^lipid, lipid^protein and protein^protein
interactions. Additionally, the release of hemoglobin
bound to the membrane could explain the extra ab-
sorbance observed in the supernatant of erythrocytes
incubated with TAM as compared to the total he-
molysis (Fig. 3B), also meaning that TAM disrupts
the binding of cytosol and cytoskeleton proteins to
Fig. 9. SDS-PAGE of erythrocyte membrane proteins isolated
from 0.33% erythrocyte suspensions preincubated at 37‡C/1 h
in the absence (Control) and in the presence of 12.5 WM TAM
(TAM). Following the preincubation, membranes were sepa-
rated and washed as described in Section 2. Samples containing
30 Wg protein were applied and the peptides were separated by
the method of Laemmli [33]. Nomenclature of the bands is giv-
en according to the classi¢cation of Fairbanks et al. [55] and
using the molecular relative weight (Mr) of markers used as
standards (Std). The gel shown is representative of three similar
separations. Arrowheads indicate the di¡erences in the protein
banding pattern between control and TAM.
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band 3, the red cell most abundant intrinsic protein.
These defects induced by TAM may contribute to
abnormal erythrocyte shape and diminished mechan-
ical stability, resulting in hemolytic anemia.
3.3. E¡ect of K-T and K-TAc on Kp of TAM and
membrane £uidity
Owing to its lipophilic character, TAM strongly
incorporates in membrane systems and its partition
is modulated by several factors, e.g. £uidity degree
and membrane composition, being higher in mem-
branes containing protein and low cholesterol con-
centration [22]. This steroid prevents TAM in-
corporation, probably due to its known e¡ects on
increasing lipid packing and surface density of
the bilayer. Furthermore, cholesterol may compete
for the microdomains where TAM incorporates,
therefore displacing the drug from the membrane
[22].
Similarly to cholesterol, K-T and K-TAc, which are
membrane stabilizers and condensing agents [49] are
expected to a¡ect the partition coe⁄cient (Kp) of
TAM, decreasing its hemolytic action. Therefore,
the Kp of TAM was estimated as a function of K-T
and K-TAc content in membrane model of DMPC
multilamellar liposomes, as summarized in Fig. 10.
These studies were carried out in liposomes of syn-
thetic lipids to minimize the very strong light scatter-
ing of suspensions and interferences in UV spectra
when ghosts and erythrocytes are used [22] not al-
lowing reliable collection of spectra data. Partition-
ing of TAM into DMPC liposomes in the liquid-
crystalline phase remarkably decreases with K-T
and K-TAc incorporation (Fig. 10), although a stron-
ger e¡ect is exhibited by K-T comparatively to K-
TAc.
To further clarify the decrease of TAM Kp upon
K-T or K-TAc incorporation in DMPC liposomes,
the e¡ects of these compounds on the £uidity of
the same membrane model were investigated by £uo-
rescence polarization. To probe the inner and the
outer regions of the bilayer two £uorophores were
Fig. 11. Fluorescence polarization (P) of DPH (A) and DPH-
PA (B) in DMPC multilamellar liposomes (345 WM) enriched
with increasing concentrations of K-T (b) and K-TAc (a) at
37‡C. The molar ratio of lipid/probe was about 400 and the de-
gree of P was determined at 336 nm excitation and 450 nm
emission using 3 nm excitation and 4 nm emission bandwidths.
The increase in P is indicative of structural condensation in the
regions probed by the £uorophores. Data are means of three
di¡erent experiments.
Fig. 10. Partition coe⁄cient (Kp) of TAM into multilamellar
DMPC liposomes enriched with K-T (b) and K-TAc (a) at
30‡C and evaluated by UV derivative spectroscopy. The Kp of
TAM decreases upon K-T and K-TAc incorporation. Each value
represents the average of three independent experiments.
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used, DPH preferentially located in the hydrophobic
core of the membrane and DPH-PA that distributes
close to the interfacial region, probing the outer bi-
layer regions [50,51].
Fig. 11 displays the e¡ects of K-T and K-TAc on
the £uidity of DMPC membranes, as evaluated by
the £uorescence polarization of DPH (Fig. 11A) and
DPH-PA (Fig. 11B). K-T increases the polarization
of the £uorophores, meaning an increase in the struc-
tural order of lipids across all the thickness of the
bilayer [52]. K-TAc slightly increases the polarization
of DPH, but not of DPH-PA. This e¡ect of K-TAc is
in agreement with its high hydrophobic character
and its location predominantly in the central regions
of the bilayer [53], apart from the cooperativity re-
gion that determines the structural order. A correla-
tion can be established between the extent of K-T and
K-TAc e¡ects on TAM Kp and on membrane £uid-
ity, similarly to that described elsewhere for choles-
terol [22]. Therefore, the inhibition of TAM-induced
hemolysis by K-T and K-TAc may be due to a stabi-
lization of the erythrocyte membrane, decreasing the
incorporation of TAM and preventing the physical
damage of the erythrocyte membrane resulting from
TAM accumulation.
In conclusion, the results described, together with
previous data [24,28,54], point to a prominent role of
TAM in inducing defects in erythrocyte membrane
structure, leading to changes in normal erythrocyte
shape and decreased mechanical stability, resulting in
hemolytic anemia. Hence, the inhibition of TAM-in-
duced hemolysis by K-T and K-TAc can be regarded
as a potential preventive procedure against toxic ef-
fects exerted by this anticancer drug in normal tis-
sues. Since cell leakage is a ¢nal stage of cytotoxicity,
the disruption of the structural characteristics of bio-
membranes by TAM may also contribute for its mul-
tiple mechanisms of anticancer action not related to
the estrogen receptors.
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